Live Chat ×
Skip to main content

New-Generation MIGS: Which MIGS for Which Patient? - Thursday, August 20, 2020, 7:00 PM EDT


CME Webinar
Thursday, August 20, 2020
7:00 PM - 8:30 PM EDT

CLICK HERE TO REGISTER

NOTE: You will be asked to "sign in" or "sign up" to register for the program and then complete a short pretest. Upon registration, a link to access the webinar will be sent in a confirmation email.


Please contact info@mededicus.com with any questions. Thank you!


FACULTY
Joseph F. Panarelli, MD
Associate Professor of Ophthalmology
Chief, Division of Glaucoma Services
Glaucoma Fellowship Director
NYU Langone Eye Center
New York, New York

Arsham Sheybani, MD
Assistant Professor of Ophthalmology
Fellowship Director, Glaucoma and Anterior Segment Surgery
Residency Program Director, Ophthalmology
Washington University in St Louis
St Louis, Missouri

CONTENT CONTRIBUTORS
Ike K. Ahmed, MD, FRCSC (Chair)
Professor
University of Utah
Salt Lake City, Utah
Assistant Professor
Director, Glaucoma and Advanced Anterior Segment Surgery (GAASS) Fellowship
Research Director, Kensington Eye Institute
University of Toronto
Toronto, Canada

Sahar Bedrood, MD, PhD
Ophthalmologist
Acuity Eye Group
Adjunct Clinical Assistant Professor
USC Roski Eye Institute
Los Angeles County + USC Medical Center
Pasadena, California

Brian A. Francis, MD, MS
Stieger Endowed Chair
Professor of Ophthalmology
Doheny and Stein Eye Institutes
Department of Ophthalmology
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

Davinder S. Grover, MD, MPH
President
Dallas Academy of Ophthalmology
Attending Surgeon and Clinician
Glaucoma Associates of Texas
Dallas, Texas

Jonathan S. Myers, MD
Director, Glaucoma Service
Wills Eye Hospital
Associate Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

CONTINUING MEDICAL EDUCATION INFORMATION

Learning Method and Medium
This educational activity consists of a webinar and five (5) study questions. The participant should, in order, read the learning objectives, participate in the webinar, answer all questions in the post test, and complete the evaluation. To receive credit for this activity, please complete the post test and evaluation. This educational activity should take a maximum of 1.5 hours to complete.

Activity Description
Patients on maximum medical therapy for glaucoma and their physicians are often challenged to select efficacious and safe treatment options that can further lower intraocular pressure while reducing the burden of topical therapy. Several recent advances in the field of glaucoma are capable of meeting these needs, including minimally invasive glaucoma surgery (MIGS) procedures. Both the array of MIGS options and the literature supporting their use are expanding. In this interactive webinar, experts in glaucoma share their experiences with various MIGS procedures and devices and discuss patient selection, comparison of MIGS procedures and devices, the latest evidence supporting MIGS safety and efficacy, and optimization techniques. The desired results of this educational activity are to prepare clinicians to confidently incorporate MIGS into their surgical repertoire and develop the ability to select the best MIGS procedure and device according to individual patient needs and desires.

Target Audience

This educational activity is intended for glaucoma specialists and other ophthalmologists.

Learning Objectives
Upon completion of this activity, participants will be better able to:
  • Compare the characteristics of established and new MIGS procedures
  • Summarize the efficacy data of subconjunctival MIGS procedures
  • Summarize the safety data of subconjunctival MIGS procedures
  • Apply evidence to select appropriate subconjunctival MIGS procedures for a variety of patients
  • Review appropriate antimetabolite use for bleb-based MIGS

Accreditation Statement
The New York Eye and Ear Infirmary of Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This educational activity was developed and implemented in collaboration with MedEdicus LLC.

AMA Credit Designation Statement
The New York Eye and Ear Infirmary of Mount Sinai designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Grantor Statement
This continuing medical education activity is supported through an unrestricted educational grant from Allergan.

Disclosure Policy Statement
It is the policy of New York Eye and Ear Infirmary of Mount Sinai that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of the educational activity in which they are participating. They are also required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations. New York Eye and Ear Infirmary of Mount Sinai is committed to providing its learners with quality CME activities and related materials that promote improvements in healthcare and not the proprietary interests of a commercial interest and, thus, has established policies and procedures in place that identify and resolve all conflicts of interest prior to the execution or release of its educational activities. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

Disclosures
Ike K. Ahmed, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aequus BioPharma, Inc; Aerie Pharmaceuticals, Inc; Akorn, Inc; Alcon; Allergan; ArcScan, Inc; Bausch & Lomb Incorporated; Beaver-Visitec International; Beyeonics Surgical Ltd; Camras Vision, Inc; Carl Zeiss Meditec, Inc; CorNeat Vision Ltd; Ellex; ELT Sight, Inc; ElutiMed; Equinox; Genentech, Inc; Glaukos Corporation; Injectsense, Inc; IRIDEX Corporation; iSTAR; Ivantis Inc; Johnson & Johnson Vision Care, Inc; Kelotec Inc; LayerBio, Inc; Leica Microsystems; MicroOptx; MicroSurgical Technology; Minosys Cellular Devices Inc; New World Medical, Inc; Ocular Instruments; Ocular Therapeutix, Inc; Omega Ophthalmics; Polyactiva Pty Ltd; Sanoculis Ltd; Santen Inc; ScienceBased Health; Sight Sciences; Strõma Medical Corporation; Thea Pharmaceuticals Limited; Vialase, Inc; Vizzario; and W. L. Gore & Associates, Inc; Contracted Research: Aerie Pharmaceuticals, Inc; Alcon; Allergan; Camras Vision, Inc; Glaukos Corporation; Ivantis Inc; Johnson & Johnson Vision Care, Inc; New World Medical, Inc; and Santen Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Alcon; Allergan; Carl Zeiss Meditec, Inc; Johnson & Johnson Vision Care, Inc; MicroSurgical Technology; and Mundipharma International.

Sahar Bedrood, MD, PhD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Avellino Labs; Glaukos Corporation; and Santen Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Allergan and Glaukos Corporation.

Brian A. Francis, MD, MS, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Beaver-Visitec International; Diopsys, Inc; Glaukos Corporation; NeoMedix Corporation; and Valeant; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; and Bausch & Lomb Incorporated.

Davinder S. Grover, MD, MPH, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; MicroOptx; New World Medical, Inc; and Reichert, Inc; Contracted Research: Allergan; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Allergan; Bausch & Lomb Incorporated; New World Medical, Inc; and Reichert, Inc.

Jonathan S. Myers, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Aerie Pharmaceuticals, Inc; Allergan; Glaukos Corporation; MicroOptx; and Olleyes Inc; Contracted Research: Aerie Pharmaceuticals, Inc; Allergan; Diopsys, Inc; Glaukos Corporation; Haag-Streit Group; Nicox; Olleyes Inc; and Santen Inc; Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; and Allergan; Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds): Olleyes Inc.

Joseph F. Panarelli, MD,
had a financial agreement or affiliation during the past year with the following commercial interests in the form of Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus): Aerie Pharmaceuticals, Inc; Allergan; CorneaGen; Glaukos Corporation; New World Medical, Inc; and Santen Inc.

Arsham Sheybani, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan; Glaukos Corporation; Ivantis Inc; and Santen Inc.

New York Eye and Ear Infirmary of Mount Sinai Peer Review Disclosure
Kateki Vinod, MD, has no relevant commercial relationships to disclose.

Editorial Support Disclosures
Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Kimberly Corbin, CHCP; Barbara Aubel; and Michelle Ong have no relevant commercial relationships to disclose.

Disclosure Attestation
The contributing physicians listed above have attested to the following:
  1. that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
  2. that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
  3. that all reasonable clinical alternatives will be discussed when making practice recommendations.

Off-Label Discussion
This CME activity includes discussion of unlabeled and/or investigative uses of drugs and/or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for FDA-approved dosing, indications, and warnings.

New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies
https://www.nyee.edu/education/cme

CME Provider Contact Information
For questions about this activity, call 917-270-7571.

To Obtain AMA PRA Category 1 Credit
To obtain AMA PRA Category 1 Credit™ for this activity, participate in the webinar and complete the post test and evaluation. You may take the test up to 2 times. Upon registering and completing the post test, your certificate will be made available online and you can print it or file it.

Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of New York Eye and Ear Infirmary of Mount Sinai, MedEdicus LLC, or Allergan.

This CME activity is copyrighted to MedEdicus LLC ©2020. All rights reserved. 220